UroGen Pharma Ltd.
URGN
$19.46
-$0.32-1.62%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -49.94M | -43.84M | -37.51M | -23.67M | -33.40M |
| Total Depreciation and Amortization | 596.00K | 497.00K | 306.00K | 266.00K | 263.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.67M | 3.17M | 8.06M | 5.34M | 6.63M |
| Change in Net Operating Assets | 5.85M | -1.85M | 15.53M | -9.60M | 2.76M |
| Cash from Operations | -39.83M | -42.02M | -13.62M | -27.66M | -23.75M |
| Capital Expenditure | -141.00K | -44.00K | -115.00K | -96.00K | -84.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 28.55M | -25.92M | 60.74M | -106.65M | 12.08M |
| Cash from Investing | 28.41M | -25.96M | 60.62M | -106.75M | 12.00M |
| Total Debt Issued | -- | -- | 0.00 | 24.49M | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 293.00K | 34.00K | 71.00K | 15.12M | 81.64M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 3.00K | -- | 0.00 | 0.00 | 18.64M |
| Cash from Financing | 296.00K | 34.00K | 71.00K | 39.61M | 100.29M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -11.12M | -67.95M | 47.07M | -94.81M | 88.54M |